CRESEMBA 372MG LYO PWD SDV PF 1/EA ISAVUCONAZONIUM SULFATE 持证商:ASTELLAS PHARMA INC NDC:00469-0420-99 参考价格(美元):584.28
CRESEMBA SUV 372MG 1 ISAVUCONAZONIUM SULFATE 持证商:ASTELLAS PHARMA US INC NDC:00469-0420-99 参考价格(美元):416.56
CRESEMBA BP CAP 74.5MG 35 ISAVUCONAZONIUM SULFATE 持证商:ASTELLAS PHARMA US INC NDC:0469-2860-35 参考价格(美元):
-----------------------------------------------------
Astellas Receives FDA Approval for CRESEMBA(isavuconazonium sulfate)for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis
U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for the use of CRESEMBA® (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis). These are life-threatening fungal infections predominantly occurring in immunocompromised patients.
About CRESEMBA®
CRESEMBA (isavuconazonium sulfate) is the prodrug containing the active antifungal agent isavuconazole, an azole antifungal indicated for use in the treatment of invasive aspergillosis and invasive mucormycosis.
PACKAGE/LABEL DISPLAY PANEL – CRESEMBA CAPSULES 186 MG – BLISTER CARTON LABEL
DC 0469-0520-02
CRESEMBA®
(isavuconazonium sulfate) capsules
186mg*
*equivalent to 100 mg isavuconazole
Unit dose blister
14 Capsules
Rx Only